Nuvectis Pharma Investor Presentation Deck
NXP900 Potential Market Opportunity
Squamous cancer cells with hippo pathway alterations and NF2 mutated cells demonstrate high
sensitivity to NXP900 in vitro and in vivo
Estimated Incidence
Indication
Cervical
Esophageal
Metastatic Anal
NSCLC
Head & Neck
Mesothelioma
Papillary Kidney Cancer
(US)
NuvectisPharma, Inc.
Squamous cell prevalence
13,950
21,550
3,000
202,600
54,000
90%
3,000
12,000
30% a
80%
25%
90%
NF2 mutation prevalence
b
33%
13%
Estimated Addressable Patient
Population (US)
12,500
6,500
2,400
50,650
48,600
1,000
1,500
a.
The prevalence of ESCC ex-US is approximately 85%.
b. The NF2 mutation is prevalent in approximately 1-3.6% of patients in several additional solid tumors including breast, NSCLC, ovarian, bladder, melanoma and CRC
21View entire presentation